Supreme Court Leaves Mifepristone Access Unchanged- For Now

n addition to ongoing litigation, last September the Trump administration FDA, after  requests from anti-abortion organizations and state attorneys general, initiated an internal review of mifepristone’s safety.  This adds uncertainty as the agency could revise dispensing rules independently of the courts. With the FDA commissioner’s resignation this week and no permanent leader in place, the timeline for completing the review remains unclear.